Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-12
2011-04-12
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07923459
ABSTRACT:
The present invention is directed to processes for the preparation of 4-(3-methanesulfonyl-phenyl)-1-N-propylpiperidine (I) or a pharmaceutically acceptable salt thereof, which comprises: oxidizing a sulfide of the formula (II): with a catalytic oxidizing agent and an oxidant; to give a compound of the formula (III): followed by catalytic reduction of the compound of formula (III).
REFERENCES:
patent: 3326916 (1967-06-01), Creighton et al.
patent: 3539573 (1970-11-01), Schmutz et al.
patent: 4048314 (1977-09-01), Kubela et al.
patent: 4202898 (1980-05-01), Depoortere
patent: 4333942 (1982-06-01), Eistetter et al.
patent: 4415736 (1983-11-01), Ciganek et al.
patent: 4485109 (1984-11-01), Ciganek
patent: 4504660 (1985-03-01), Klaubert et al.
patent: 5462947 (1995-10-01), Svensson et al.
patent: 5502050 (1996-03-01), Gross
patent: 6175015 (2001-01-01), Yuan et al.
patent: 2003/0109532 (2003-06-01), Sonesson et al.
patent: 0060179 (1982-02-01), None
patent: 0369887 (1989-11-01), None
patent: 0094159 (1990-03-01), None
patent: 0533266 (1992-09-01), None
patent: 0533267 (1992-09-01), None
patent: 0533268 (1993-03-01), None
patent: 675118 (1995-04-01), None
patent: 0867183 (1998-09-01), None
patent: 0867183 (2004-10-01), None
patent: 1459013 (1965-05-01), None
patent: 850662 (1957-10-01), None
patent: 1060160 (1965-07-01), None
patent: 1060160 (1967-03-01), None
patent: 1560271 (1977-01-01), None
patent: 2078746 (1981-06-01), None
patent: 2083476 (1981-09-01), None
patent: 2027703 (2006-12-01), None
patent: 6510107 (1966-02-01), None
patent: 8905799 (1989-06-01), None
patent: 9109594 (1991-07-01), None
patent: 9218475 (1992-10-01), None
patent: 9300313 (1993-01-01), None
patent: 9304684 (1993-03-01), None
patent: 9811068 (1998-03-01), None
patent: 0003713 (2000-01-01), None
patent: 0078728 (2000-12-01), None
patent: 01/46144 (2001-06-01), None
patent: 01/46145 (2001-06-01), None
patent: 0146144 (2001-06-01), None
patent: 0146145 (2001-06-01), None
patent: 0146146 (2001-06-01), None
patent: 0205819 (2002-01-01), None
patent: 02059108 (2002-08-01), None
patent: 2004099150 (2004-11-01), None
patent: 2005019215 (2005-03-01), None
patent: 2005121087 (2005-12-01), None
patent: 2005121088 (2005-12-01), None
patent: 2005121092 (2005-12-01), None
patent: 2006039325 (2006-04-01), None
patent: 2006040155 (2006-04-01), None
patent: 2006040156 (2006-04-01), None
patent: 2007042295 (2007-04-01), None
patent: 2007065655 (2007-06-01), None
Sato et al., “Oxidation of sulfides to sulfoxides and sulfones with 30% hydrogen peroxide under organic solvent- and halogen-free conditions” Tetrahedron 57 (2001) pp. 2469-2476.
Radl et al., “Synthesis of piperidine analogs of 1-(3-chlorophenyl) piperazine, a well known serotonin ligand” STN Accession No. 1996:661865, Abstract of Journal of Heterocyclic Chemistry (1999), 36(4).
Rosenfeld et al., “Gas chromatographic method for analysis of butyrophenones based on the Hofmann degradation reaction” STN Accession No. 1977:60610, Abstract of Journal of Chromatography (1976), 129.
Morita et al., “Practical Application of the Palladium-catalyzed Animation in Phenylpiperazine Synthesis: An Efficient Synthesis of a Metabolite of the Antipsychotic Agent Aripiprazole”; 1998 Elsevier Science Ltd., pp. 4811-4818.
Smaill et al., “Mono-and difuntional nitrogen mustard analogues of the DNA minor groove binder pibenzimol synthesis, cytotoxity and interaction with DNA”, Anti-Cancer Drug Design (1998), vol. 13, Oxford University Press; pp. 221-242.
Beugelmans et al., “Synthese d'heterocycles a 5 et 6 chainons par une strategie combinant des reactions SNAr et SRN1”; Institut de Chimie des Substances Naturelles, 1995 vol. 132; pp. 306-313.
Egawa et al., A New Synthesis of 7H-Pyrido[1,2,3-de][1,4]benzoxazine Derivatives Including an Antibacterial Agent, Ofloxacin:; Research Labortories, Osaka, Japan; 1986 vol. 34, pp. 4098-4102.
Takai et al., “Reaction of Spiro[4H-3, 1-benzoxaxine-44′-piperidin]-2(1H)-one Derivatives and Related Compounds with Phosphorus Oxychloride”; Tokyo Research Laboratory, Tokyo, Japan; pp. 1901-1906.
Zhang et al., “Acta Pharmaceutica Sinica”; 1981; vol. 16, No. 6; pp. 414-424; Shanghai Institut of Pharmaceutical Industrial Research; Shanghai.
Klaubert et al., “N-(Aminohenyl)oxamic Acids and Esters as Potent, Orally Active Antiallergy Agents”; 1989 American Chemical Society; Research Division, Wyeth Laboratories Inc., Radnor, Pennsylvania; Journal of Medicinal Chemistry, vol. 24; pp. 742-748.
Self et al., “Cine and tele Substitutions in the Reaction of 2,3-Dinitroaniline with Secondary Amines”; J.C.S. Chem. Comm., 1980; pp. 281-282.
Elslager et al., “Folate Antagonists. 3. 2,4-Diamino-6-(heterocyclic)quinazolines, a Novel Class of Antimetabolits with Potent Antimalarial and Antibacterial Activity”; Journal of Medicinal Chemistry; 1972 vol. 15, No. 87; pp. 826-836; Department of Chemistry, Research and Development Division, Ann Arbor, Michigan.
Berberian et al., “Comparison of Schistosomicidal Activity of Xanthenones and 4-Methyl-3-chloroanilines and Their Hydroxymethyl Analogs in Swiss Mice and Syrian Hamsters Infected withSchistosoma mansoni”; Sterlin-Winthrop Research Institute, Rensselaer, New York, pp. 607-610, 1969.
David W. Henry, A Facile Synthesis of Piperazines from Primary Amines (1); Department of Pharmaceutical Chemistry, Stanford Research Institute; Dec. 1966; pp. 503-511.
Bergel et al., Synthetic Analgesics, Part 1. Synthesis of Basic Benzofuran Derivatives and Certain 4-Phenylpiperidine Compounds; 1944; pp. 261-265.
Nacci et al., “Antiblastic substances L11. Tylophorien analogs. 1. Synthesis and cytostotic and cytotoxic activity of 4-(3,4-dimethoxphenyl)piperidine”; Farmaco E. Scintifica 1972, 328, (5) pp. 399-410.
Sonesson et al., “Substituted (S)-Phenylpiperidines and Rigid Congeners as Preferential Dopamine Autoreceptor Antagonists: Synthesis and Structure-Activity Relationships”; Journal of Medicinal Chemistry, 1994 American Chemical Society; pp. 2735-2752.
Radl et al., “Synthesis of Piperidine Analogs of 1-(3-Chlorophenyl)piperazine, a Well Known Serotonin Ligand”; Research Institute for Pharmacy and Biochemistry, Prague, Czech Republic; pp. 1017-1022, 1999.
Altomare et al., Quantitative Structure-Metabolim Relationship Analyses of MAO-Medicated Toxication of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Alalogues; Chem. Res. Toxicol, 1992, vol. 5, pp. 366-375.
Carlsson et al., Interactions between glutamatergic and monoaminergic systems within the basal nanglia—implications for schizophrenia and Parkinson's disease; Department of Pharmacology, University of Goteborg, Goteborg, Sweden; 1990 Elsevier Science Publishers, vol. 13, No. 7, 1990; pp. 272-276.
Coyle et al., “Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation”; Science, vol. 219, Johns Hopkins School of Medicine, Baltimore, Maryland; pp. 1184-1190, 1983.
Feldman et al., 1993; “Mind-Altering Drugs”; Chapter 17; pp. 731, 762 and 763.
Grunblatt et al., “Potent neuroprotective and antioxidant activity of apomorhine in PMTP and 6-hydroxydopamine induced neurotoxicity”; Journal Neural transm. (1999) [Suppl]I pp. 57-70.
Grunblatt et al., “Neuroprotective Strategies in Parkinson's Disease Using Models of 6-Hydroxydopamine and MPTP”; Bruce Rappaport Family Research Institute and Department of Pharmacology, Haifa, Israel; pp. 262-273, 2000.
Philip G. Strange; “Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects”; School of Animal and Microbial Sciences, University of Reading, Whiteknights, Reading, United Kingdom, vol. 53, No. 1; pp. 119-133, 2001.
Manfred E. Wolff; “Antipsychotic Agents, 4.1 Biologic Test Methods”; Burger's Medicinal Chemistry; 4th Edition, Part III; John Wiley & Sons; 1979, pp. 872-873.
Roth
Desmond Richard
Devine Paul N.
Gauthier Donald R.
Birch & Stewart Kolasch & Birch, LLP
Desai Rita J
Mabry John
NSAB, Filial AF Neurosearch Sweden AB, Sverige
LandOfFree
Process for the synthesis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the synthesis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the synthesis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730275